ArticleMetabolomics : Official journal of the Metabolomic Society2026
Metabolomic signatures suggest altered bile acid and energy metabolism in CRB1- retinopathies.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe human CRB1 gene encodes the CRB1 protein, primarily expressed in retinal Muller cells and photoreceptors, where it regulates apical-basal polarity and cellular signalling through its role in adherence junctions and maintaining the outer limiting membrane barrier. Dysfunction of CRB1 results in a range of retinal phenotypes with few systemic implications reported. It has been suggested that disrupted Crb1 expression in the gastrointestinal epithelium of rd8 mouse models (Crb1
objectiveWhole metabolomic analysis in patients can provide further insights into disease pathophysiology and aid the identification of potential systemic biomarkers.
methodsBlood plasma from 25 molecularly confirmed CRB1-retinopathy patients from Moorfields Eye Hospital with 25 age- and gender-matched healthy controls underwent ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). MetaboLync pathway analysis identified affected metabolic pathways.
resultsOf 872 compounds, 244 were significantly altered in CRB1 patients. Key findings included disrupted bile acid metabolism, with elevated primary and secondary bile acids alongside increased gut microbial phenylalanine pathway metabolites, indicative of altered gut microbiome-related metabolic activity and altered enterohepatic circulation. However, sucrose and butyrate levels remained unchanged amongst groups, suggesting absence of metabolomic evidence for severe intestinal barrier dysfunction. Reductions in antioxidants and neuroprotective agents were found alongside energy metabolism dysregulation.
conclusionThese findings reveal metabolic dysregulation in CRB1-retinopathy, including altered gut microbiome-related metabolic activity, and no strong metabolomic evidence of severe intestinal barrier disruption. The reductions in antioxidants, energy pathways and neuroprotective agents highlight potential therapeutic targets to delay disease progression. Further investigation into gut microbiome composition and intestinal permeability in humans with CRB1 retinopathies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.